Anti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance DOI

Josephine Harrington,

Stormi E. Gale, Amanda R. Vest

et al.

Circulation Heart Failure, Journal Year: 2024, Volume and Issue: 17(9)

Published: Aug. 1, 2024

Obesity is a significant risk factor for heart failure (HF) development, particularly HF with preserved ejection fraction and as result, many patients also have obesity. There growing clinical interest in optimizing strategies the management of obesity across spectrums both disease severity. The emergence anti-obesity medications cardiovascular outcomes benefits, principally glucagon-like peptide-1 receptor agonists, has made it possible to study impact baseline conditions, including HF. However, trials data supporting safety efficacy treating currently limited fraction, but do confirm weight loss this patient population well improvements functional status, biomarkers inflammation stability. Here, we review current available surrounding HF, limitations evidence ongoing areas investigation, summarize next phase emerging provide practical advice multidisciplinary

Language: Английский

Obesity and cardiovascular disease: an ESC clinical consensus statement DOI Creative Commons
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades

et al.

European Heart Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 30, 2024

The global prevalence of obesity has more than doubled over the past four decades, currently affecting a billion individuals. Beyond its recognition as high-risk condition that is causally linked to many chronic illnesses, been declared disease per se results in impaired quality life and reduced expectancy. Notably, two-thirds obesity-related excess mortality attributable cardiovascular disease. Despite increasingly appreciated link between broad range manifestations including atherosclerotic disease, heart failure, thromboembolic arrhythmias, sudden cardiac death, underrecognized sub-optimally addressed compared with other modifiable risk factors. In view major repercussions epidemic on public health, attention focused population-based personalized approaches prevent weight gain maintain healthy body from early childhood throughout adult life, well comprehensive loss interventions for persons established obesity. This clinical consensus statement by European Society Cardiology discusses current evidence epidemiology aetiology obesity; interplay obesity, factors conditions; management patients strategies lifestyle changes, interventional procedures, anti-obesity medications particular focus their impact cardiometabolic outcomes. document aims raise awareness factor provide guidance implementing evidence-based practices prevention optimal within context primary secondary prevention.

Language: Английский

Citations

53
Prevention of cardiorenal complications in people with type 2 diabetes and obesity DOI Creative Commons
Daniel J. Drucker

Cell Metabolism, Journal Year: 2024, Volume and Issue: 36(2), P. 338 - 353

Published: Jan. 9, 2024

Language: Английский

Citations

22
Obesity and cardiovascular disease: an ESC clinical consensus statement DOI Creative Commons
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades

et al.

European Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 30, 2024

The global prevalence of obesity has more than doubled over the past four decades, currently affecting a billion individuals. Beyond its recognition as high-risk condition that is causally linked to many chronic illnesses, been declared disease per se results in impaired quality life and reduced expectancy. Notably, two-thirds obesity-related excess mortality attributable cardiovascular disease. Despite increasingly appreciated link between broad range manifestations including atherosclerotic disease, heart failure, thromboembolic arrhythmias, sudden cardiac death, underrecognized sub-optimally addressed compared with other modifiable risk factors. In view major repercussions epidemic on public health, attention focused population-based personalized approaches prevent weight gain maintain healthy body from early childhood throughout adult life, well comprehensive loss interventions for persons established obesity. This clinical consensus statement by European Society Cardiology discusses current evidence epidemiology aetiology obesity; interplay obesity, factors conditions; management patients strategies lifestyle changes, interventional procedures, anti-obesity medications particular focus their impact cardiometabolic outcomes. document aims raise awareness factor provide guidance implementing evidence-based practices prevention optimal within context primary secondary prevention.

Language: Английский

Citations

16
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines DOI Creative Commons
Sten Madsbad, Jens J. Holst

Expert Opinion on Investigational Drugs, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 19

Published: March 1, 2025

Introduction GLP-1-based therapies have changed the treatment of overweight/obesity. Liraglutide 3.0 mg daily, first GLP-1 RA approved for overweight, induced a weight loss 6–8%, Semaglutide 2.4 once weekly improved to about 12–15%, while dual GIP/GLP-1 receptor agonist tirzepatide has 20% in obese people without diabetes.

Language: Английский

Citations

2
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure? DOI Creative Commons
Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(9), P. 2112 - 2112

Published: Sept. 16, 2024

Obesity is a significant predisposing factor for heart failure with preserved ejection fraction (HFpEF). Although substantial proportion of individuals HFpEF also have obesity, those obesity are under-represented in clinical trials failure. In turn, current guidelines provided limited recommendations the medical management this patient population. Both and diabetes induce pro-inflammatory state that can contribute to endothelial dysfunction coronary microvascular impairment, finally resulting HFpEF. Additionally, leads increased epicardial chest wall adiposity, which enhances ventricular interdependence. This condition further aggravated by plasma blood volume expansion excessive vasoconstriction, ultimately worsening Despite well-documented benefits GLP-1 receptor agonists subjects diabetes, or both, their role obesity-related remains unclear. light recently published literature, review aims investigate potential mechanisms synthesize available evidence regarding patients

Language: Английский

Citations

14
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions DOI Open Access
Kyriazoula Chatzianagnostou, Melania Gaggini,

Adrian Suman Florentin

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(11), P. 6218 - 6218

Published: June 5, 2024

Although good glycemic control in patients with type 2 diabetes (T2D) can prevent cardiovascular complications, many diabetic still have poor optimal control. A new class of antidiabetic drugs (e.g., glucagon-like peptide-1-GLP-1 receptor agonists, sodium-glucose co-transporters-SGLT2 inhibitors), addition to the low hypoglycemic effect, exert multiple beneficial effects at a metabolic and level, through mechanisms other than antihyperglycemic agents. This review aims discuss these drugs, highlighting benefits, description their action as well available data by preclinical clinical studies. Moreover, innovative tools T2D field will be described which may help advance towards better targeted personalized care future.

Language: Английский

Citations

9
Influence of Obesity on Invasive Hemodynamics and Prognosis in Patients With Heart Failure DOI
Benjamin Lautrup Hansen, Tania Deis,

Johan Larsson

et al.

JACC Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

1
New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review DOI Open Access
Jorge Jalil, Luigi Gabrielli, María Paz Ocaranza

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(8), P. 4407 - 4407

Published: April 17, 2024

This review examines the impact of obesity on pathophysiology heart failure with preserved ejection fraction (HFpEF) and focuses novel mechanisms for HFpEF prevention using a glucagon-like peptide-1 receptor agonism (GLP-1 RA). Obesity can lead to through various mechanisms, including low-grade systemic inflammation, adipocyte dysfunction, accumulation visceral adipose tissue, increased pericardial/epicardial tissue (contributing an increase in myocardial fat content interstitial fibrosis). Glucagon-like peptide 1 (GLP-1) is incretin hormone that released from enteroendocrine L-cells gut. GLP-1 reduces blood glucose levels by stimulating insulin synthesis, suppressing islet α-cell function, promoting proliferation differentiation β-cells. regulates gastric emptying appetite, RA currently indicated treating type 2 diabetes (T2D), obesity, metabolic syndrome (MS). Recent evidence indicates may play significant role preventing patients MS, or obese T2D. effect be due activating cardioprotective (the endogenous counter-regulatory renin angiotensin system AMPK/mTOR pathway) inhibiting deleterious remodeling PKA/RhoA/ROCK pathway, aldosterone levels, microinflammation). However, there still need further research validate these humans.

Language: Английский

Citations

8
Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies DOI
Anand Athavale, Eri Fukaya, Nicholas J. Leeper

et al.

Arteriosclerosis Thrombosis and Vascular Biology, Journal Year: 2024, Volume and Issue: 44(6), P. 1165 - 1170

Published: May 22, 2024

Language: Английский

Citations

7
Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities DOI Creative Commons
Riccardo Sarzani, Matteo Landolfo,

Chiara Di Pentima

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: April 8, 2024

Obesity is a multifactorial chronic disease characterized by an excess of adipose tissue, affecting people all ages. In the last 40 years, incidence overweight and obesity almost tripled worldwide. The accumulation “visceral” tissue increases with aging, leading to several cardio-metabolic consequences: from increased blood pressure overt arterial hypertension, insulin-resistance type 2 diabetes mellitus (T2DM), dyslipidemia, kidney (CKD), obstructive sleep apnea. increasing use innovative drugs, namely glucagon-like peptide-1 receptor agonists (GLP1-RA) sodium-glucose cotransporter-2 inhibitors (SGLT2-i), changing management its related cardiovascular complications significantly. These first considered only for T2DM treatment, are now used in patients visceral adiposity or obese patients, as no longer just risk factor but critical condition at basis common metabolic, cardiovascular, renal diseases. An adipocentric vision approach should become cornerstone integrated reducing avoiding onset obesity-related multiple factors their clinical complications. According recent progress basic research on adiposity, this narrative review aims contribute novel focusing pathophysiological therapeutic insights.

Language: Английский

Citations

6